<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04454762</url>
  </required_header>
  <id_info>
    <org_study_id>CaboCHILD</org_study_id>
    <nct_id>NCT04454762</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function</brief_title>
  <acronym>CaboCHILD</acronym>
  <official_title>A Phase II Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma (HCC) and Impaired Liver Function (Child-Pugh Score B7-8)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Interdisciplinary Center Clinical Trials (IZKS), University Medical Center Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an prospective, interventional, non-randomized multicenter phase II study to evaluate&#xD;
      the safety, tolerability and efficacy of Cabozantinib as a second-line therapy (after one&#xD;
      prior systemic therapy) in patients with intermediate to advanced HCC (BCLC B/C) and&#xD;
      concomitant impaired liver function CP score B7-8. Subjects who meet all study eligibility&#xD;
      criteria will receive Cabozantinib 40 mg daily orally. Subjects will receive Cabozantinib as&#xD;
      long as they continue to experience clinical benefit in the opinion of the Investigator or&#xD;
      until there is unacceptable toxicity or the need for subsequent systemic anti-cancer&#xD;
      treatment or liver directed local anti-cancer therapy. Treatment may continue in this fashion&#xD;
      after radiographic progression as long as the Investigator believes that the subject is still&#xD;
      receiving clinical benefit from Cabozantinib and that the potential benefit of continuing&#xD;
      Cabozantinib outweighs potential risk. In addition, all subjects will be treated with best&#xD;
      supportive care. This excludes systemic anti-cancer therapy and liver-directed local&#xD;
      anti-cancer therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) [Safety and Tolerability]</measure>
    <time_frame>Through study completion, up to approximately 2 years</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinue Study Treatment Due to Adverse Events (AEs) [Safety and Tolerability]</measure>
    <time_frame>Through study completion, up to approximately 2 years</time_frame>
    <description>The number of participants who discontinue study treatment due to an AE will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ALBI [Safety and Tolerability]</measure>
    <time_frame>Through study completion, up to approximately 2 years</time_frame>
    <description>Assessment of the Albumin-Bilirubin (ALBI) Grade. Grade range 1-3, with 3 indicating greatest severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECOG [Safety and Tolerability]</measure>
    <time_frame>Through study completion, up to approximately 2 years</time_frame>
    <description>Eastern Cooperative Oncology Group (ECOG) performance status. Score range 0 (normal activity) to 5 (dead).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Child-Pugh [Safety and Tolerability]</measure>
    <time_frame>Through study completion, up to approximately 2 years</time_frame>
    <description>Used to assess the prognosis of chronic liver disease. Classification of severity of liver disease according to the degree of ascites, total bilirubin and albumin, prothrombin time, and degree of encephalopathy. Each measure is scored 1-3, with 3 indicating greatest severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure [Safety and Tolerability]</measure>
    <time_frame>Through study completion, up to approximately 2 years.</time_frame>
    <description>mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Through study completion, up to approximately 2 years</time_frame>
    <description>The time between first application of trial medication to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Through study completion, up to approximately 2 years</time_frame>
    <description>PFS is defined as the time from first intake of trial medication to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Through study completion, up to approximately 2 years</time_frame>
    <description>The response rate is defined as the percentage of subjects with a confirmed reduction in tumor size compared to baseline as well as fulfilling the criteria for complete or partial response according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of Cabozantinib administration.</measure>
    <time_frame>6 weeks</time_frame>
    <description>The plasma concentration of Cabozantinib and possible relevant metabolites will be measured in PK samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQOL)</measure>
    <time_frame>Through study completion, up to approximately 2 years</time_frame>
    <description>Assessed by the validated German version of the Chronic Liver Disease Questionnaire (CLDQ-D). The questionnaire contains 29 items which can be grouped into the liver-disease specific domains like activity, fatigue, worries, abdominal symptoms, and systemic symptoms. Each category can be judged separately between the groups. The results of the CLDQ-D score are presented on a 7-point Likert scale. Higher results indicate better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cabozantinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 20 mg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>oral administration (40 mg daily, reduced dose 20 mg daily)</description>
    <arm_group_label>Cabozantinib</arm_group_label>
    <other_name>Cabometyx</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria:&#xD;
&#xD;
          1. Written informed consent&#xD;
&#xD;
          2. Age ≥ 18&#xD;
&#xD;
          3. Histological/cytological or non-invasive (according to EASL/AASLD guidelines)&#xD;
             diagnosis of HCC&#xD;
&#xD;
          4. Availability of a recent (up to 28 days old) CT/MRI images of thorax and abdomen&#xD;
&#xD;
          5. Subject's HCC is not amenable to a curative treatment approach (e.g., transplant,&#xD;
             surgery, radiofrequency ablation) corresponding to BCLC classification B/C&#xD;
&#xD;
          6. Progression or toxicities following one prior systemic therapy for HCC&#xD;
&#xD;
          7. Recovery to ≤ grade 1 from toxicities related to any prior treatments, unless the&#xD;
             adverse events are clinically non-significant and/or stable on supportive therapy&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
          9. Adequate hematologic function, based upon meeting the following laboratory criteria&#xD;
             within 7 days before enrollment: absolute neutrophil count (ANC) ≥ 1200/mm3 (≥ 1.2 x&#xD;
             109/L); platelets ≥ 60,000/mm3 (≥ 60 x 109/L); hemoglobin ≥ 8 g/dL (≥ 80 g/L)&#xD;
&#xD;
         10. Adequate renal function, based upon meeting the following laboratory criteria within 7&#xD;
             days before enrollment: serum creatinine ≤ 1.5 × upper limit of normal or calculated&#xD;
             creatinine clearance ≥ 40 mL/min (using the Cockcroft-Gault equation)&#xD;
&#xD;
         11. Liver function Child-Pugh (CP) score B7-8&#xD;
&#xD;
         12. ALBI (albumin-bilirubin) grade 1-2&#xD;
&#xD;
         13. Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) &lt; 7.0 × upper&#xD;
             limit of normal (ULN) within 7 days before enrollment&#xD;
&#xD;
         14. Antiviral therapy per local standard of care if active hepatitis B (HBV) infection&#xD;
&#xD;
         15. Capability to understand and comply with the protocol requirements (e.g. sufficient&#xD;
             knowledge of German language to answer the questionnaires, ability to swallow intact&#xD;
             tablets).&#xD;
&#xD;
        Main exclusion criteria:&#xD;
&#xD;
          1. Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma&#xD;
&#xD;
          2. Receipt of more than 1 prior systemic therapy for advanced HCC. Additional prior&#xD;
             systemic therapies used as adjuvant therapy are allowed.&#xD;
&#xD;
          3. Any type of anti-cancer agent (including investigational) within 2 weeks before&#xD;
             enrollment&#xD;
&#xD;
          4. Radiation therapy within 4 weeks (2 weeks for radiation for bone metastases) or&#xD;
             radionuclide treatment (e.g., I-131 or Y-90) within 6 weeks of enrollment. Subject&#xD;
             cannot be enrolled if there are any clinically relevant ongoing complications from&#xD;
             prior radiation therapy.&#xD;
&#xD;
          5. Prior Cabozantinib treatment&#xD;
&#xD;
          6. Known brain metastases or cranial epidural disease unless adequately treated with&#xD;
             radiotherapy and/or surgery (including radiosurgery) and stable for at least 3 months&#xD;
             before enrollment. Eligible subjects must be without corticosteroid treatment at the&#xD;
             time of enrollment.&#xD;
&#xD;
          7. Concomitant anticoagulation, at therapeutic doses, with anticoagulants such as&#xD;
             warfarin or warfarin-related agents, low molecular weight heparin (LMWH), thrombin or&#xD;
             activated coagulation factor X (FXa) inhibitors, or antiplatelet agents (e.g.,&#xD;
             clopidogrel). Low-dose aspirin for cardioprotection (per local applicable guidelines),&#xD;
             low-dose warfarin (≤ 1 mg/day), and low-dose LMWH are permitted.&#xD;
&#xD;
          8. The subject has uncontrolled, significant intercurrent or recent illness including,&#xD;
             but not limited to, the following conditions:&#xD;
&#xD;
               -  Cardiovascular disorders including: Symptomatic congestive heart failure,&#xD;
                  instable angina pectoris, or serious cardiac arrhythmias, uncontrolled&#xD;
                  hypertension defined as sustained BP &gt; 150 mm Hg systolic, or &gt; 100 mm Hg&#xD;
                  diastolic despite optimal antihypertensive treatment, stroke (including TIA),&#xD;
                  myocardial infarction, or other ischemic event within 6 months before enrollment,&#xD;
                  thromboembolic event within 3 months before enrollment. Subjects with thromboses&#xD;
                  of portal/hepatic vasculature attributed to underlying liver disease and/or liver&#xD;
                  tumor are eligible&#xD;
&#xD;
               -  Gastrointestinal (GI) disorders including those associated with a high risk of&#xD;
                  perforation or fistula formation: tumors invading the GI tract, active peptic&#xD;
                  ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis,&#xD;
                  symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction&#xD;
                  of the pancreatic duct or common bile duct, or gastric outlet obstruction;&#xD;
                  abdominal fistula, GI perforation, bowel obstruction, intra-abdominal abscess&#xD;
                  within 6 months before enrollment, Note: Complete healing of an intra-abdominal&#xD;
                  abscess must be confirmed prior to enrollment&#xD;
&#xD;
               -  Major surgery within 2 months before enrollment. Complete healing from major&#xD;
                  surgery must have occurred 1 month before enrollment. Complete healing from minor&#xD;
                  surgery (e.g., simple excision, tooth extraction) must have occurred at least 7&#xD;
                  days before enrollment. Subjects with clinically relevant complications from&#xD;
                  prior surgery are not eligible&#xD;
&#xD;
               -  Cavitating pulmonary lesion(s) or endobronchial disease&#xD;
&#xD;
               -  Lesion invading a major blood vessel (e.g., pulmonary artery or aorta)&#xD;
&#xD;
               -  Clinically significant bleeding risk within 3 months of enrollment including the&#xD;
                  following: hematuria, hematemesis, hemoptysis of &gt; 0.5 teaspoon (&gt; 2.5 mL) of red&#xD;
                  blood, or other signs indicative of pulmonary hemorrhage, or history of other&#xD;
                  significant bleeding if not due to reversible external factors&#xD;
&#xD;
               -  Other clinically significant disorders such as: Active infection requiring&#xD;
                  systemic treatment, known infection with human immunodeficiency virus (HIV) or&#xD;
                  known acquired immunodeficiency syndrome (AIDS)-related illness; serious&#xD;
                  non-healing wound/ulcer/bone fracture; malabsorption syndrome;&#xD;
                  uncompensated/symptomatic hypothyroidism; requirement for hemodialysis or&#xD;
                  peritoneal dialysis; history of solid organ transplantation&#xD;
&#xD;
          9. Subjects with untreated or incompletely treated varices with bleeding or high risk for&#xD;
             bleeding are excluded with the following clarification: subjects with history of prior&#xD;
             variceal bleeding must have been treated with adequate endoscopic therapy without any&#xD;
             evidence of recurrent bleeding for at least 6 months prior to study entry and must be&#xD;
             stable on optimal medical management (e.g. non-selective beta blocker, proton pump&#xD;
             inhibitor) at study entry.&#xD;
&#xD;
         10. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.&#xD;
&#xD;
         11. Women of child-bearing potential (WOCBP) and men who are able to father a child,&#xD;
             unwilling to be abstinent or use highly effective methods of birth control that result&#xD;
             in a low failure rate of less than 1% per year when used consistently and correctly&#xD;
             beginning at informed consent, for the duration of study participation and for at&#xD;
             least 4 months after last dose of the study drug. Because oral contraceptives might&#xD;
             possibly not be considered as &quot;effective methods of contraception&quot; during the&#xD;
             treatment with Cabozantinib, they should be used together with another method, such as&#xD;
             a barrier method.&#xD;
&#xD;
         12. Currently receiving any other investigational agent or received an investigational&#xD;
             agent within 30 days (or within 5 times the half-life of this agent or its relevant&#xD;
             metabolites, the longer period will apply) before the first dose of Cabozantinib.&#xD;
&#xD;
         13. Hepatic encephalopathy Grad I-IV according to CP classification (≥ 2 points) and West&#xD;
             Haven Criteria&#xD;
&#xD;
         14. Moderate or severe ascites according to CP classification (≥ 3 points)&#xD;
&#xD;
         15. Corrected QT interval calculated by the Fridericia formula (QTcF) &gt; 500 ms within 7&#xD;
             days before enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus-Alexander Wörns, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Mainz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcus-Alexander Wörns, Prof. MD</last_name>
    <phone>+49 6131 177389</phone>
    <email>marcus-alexander.woerns@unimedizin-mainz.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Internal Medicine I, Johannes Gutenberg University Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus-Alexander Wörns, Prof. MD</last_name>
      <phone>+49 6131 177389</phone>
      <email>marcus-alexander.woerns@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Marcus-Alexander Wörns</investigator_full_name>
    <investigator_title>Senior consultant, Department of Internal Medicine I</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>HCC</keyword>
  <keyword>Child-Pugh</keyword>
  <keyword>cabozantinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04454762
org study id: CaboCHILD
nct id: NCT04454762
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
This is an prospective, interventional, non-randomized multicenter phase II study to evaluate
      the safety, tolerability and efficacy of Cabozantinib as a second-line therapy (after one
      prior systemic therapy) in patients with intermediate to advanced HCC (BCLC B/C) and
      concomitant impaired liver function CP score B7-8. Subjects who meet all study eligibility
      criteria will receive Cabozantinib 40 mg daily orally. Subjects will receive Cabozantinib as
      long as they continue to experience clinical benefit in the opinion of the Investigator or
      until there is unacceptable toxicity or the need for subsequent systemic anti-cancer
      treatment or liver directed local anti-cancer therapy. Treatment may continue in this fashion
      after radiographic progression as long as the Investigator believes that the subject is still
      receiving clinical benefit from Cabozantinib and that the potential benefit of continuing
      Cabozantinib outweighs potential risk. In addition, all subjects will be treated with best
      supportive care. This excludes systemic anti-cancer therapy and liver-directed local
      anti-cancer therapy.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Incidence of Adverse Events (AEs) [Safety and Tolerability]
time frame: Through study completion, up to approximately 2 years
description: An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented.
measure: Number of Participants Who Discontinue Study Treatment Due to Adverse Events (AEs) [Safety and Tolerability]
time frame: Through study completion, up to approximately 2 years
description: The number of participants who discontinue study treatment due to an AE will be presented.
measure: ALBI [Safety and Tolerability]
time frame: Through study completion, up to approximately 2 years
description: Assessment of the Albumin-Bilirubin (ALBI) Grade. Grade range 1-3, with 3 indicating greatest severity
measure: ECOG [Safety and Tolerability]
time frame: Through study completion, up to approximately 2 years
description: Eastern Cooperative Oncology Group (ECOG) performance status. Score range 0 (normal activity) to 5 (dead).
measure: Child-Pugh [Safety and Tolerability]
time frame: Through study completion, up to approximately 2 years
description: Used to assess the prognosis of chronic liver disease. Classification of severity of liver disease according to the degree of ascites, total bilirubin and albumin, prothrombin time, and degree of encephalopathy. Each measure is scored 1-3, with 3 indicating greatest severity
measure: Blood pressure [Safety and Tolerability]
time frame: Through study completion, up to approximately 2 years.
description: mmHg
measure: Overall survival (OS)
time frame: Through study completion, up to approximately 2 years
description: The time between first application of trial medication to date of death due to any cause.
measure: Progression-free survival (PFS)
time frame: Through study completion, up to approximately 2 years
description: PFS is defined as the time from first intake of trial medication to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm.
measure: Objective response rate (ORR)
time frame: Through study completion, up to approximately 2 years
description: The response rate is defined as the percentage of subjects with a confirmed reduction in tumor size compared to baseline as well as fulfilling the criteria for complete or partial response according to RECIST 1.1.
measure: Pharmacokinetics (PK) of Cabozantinib administration.
time frame: 6 weeks
description: The plasma concentration of Cabozantinib and possible relevant metabolites will be measured in PK samples.
measure: Health-related quality of life (HRQOL)
time frame: Through study completion, up to approximately 2 years
description: Assessed by the validated German version of the Chronic Liver Disease Questionnaire (CLDQ-D). The questionnaire contains 29 items which can be grouped into the liver-disease specific domains like activity, fatigue, worries, abdominal symptoms, and systemic symptoms. Each category can be judged separately between the groups. The results of the CLDQ-D score are presented on a 7-point Likert scale. Higher results indicate better quality of life.
arm group label: Cabozantinib
arm group type: Experimental
description: 40 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 20 mg daily.
intervention type: Drug
intervention name: Cabozantinib
description: oral administration (40 mg daily, reduced dose 20 mg daily)
arm group label: Cabozantinib
other name: Cabometyx
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Marcus-Alexander Wörns, Prof. MD
role: Principal Investigator
affiliation: University Medical Center Mainz
last name: Marcus-Alexander Wörns, Prof. MD
phone: +49 6131 177389
email: marcus-alexander.woerns@unimedizin-mainz.de
facility: 
status: Recruiting
contact: 
country: Germany
responsible party type: Principal Investigator
investigator affiliation: Johannes Gutenberg University Mainz
investigator full name: Marcus-Alexander Wörns
investigator title: Senior consultant, Department of Internal Medicine I
mesh term: Carcinoma
mesh term: Carcinoma, Hepatocellular